Adverum prepares pivotal study for wet AMD gene therapy, touts Phase 2 data

Max Gelman

Senior Editor

Adverum Biotechnologies’ eye disease gene therapy has traversed a rocky road of safety troubles, but the company — presenting new Phase 2 data in wet AMD …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Adverum prepares pivotal study for wet AMD gene therapy, touts Phase 2 data

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Ad­verum pre­pares piv­otal study for wet AMD gene ther­a­py, touts Phase 2 da­ta

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Adverum prepares pivotal study for wet AMD gene therapy, touts Phase 2 data